Storys zum Thema Pharmaindustrie
-
Sprache:
Englisch
- Medien:
- Zeitraum:
- Zeitraum:Gesamt
- mehr
Sysmex Inostics' updated SafeSEQ Breast Cancer Panel advances novel clinical uses of ctDNA through quantitative testing
Baltimore, Maryland (ots) - Building on the ultra-high sensitivity SafeSEQ Breast Cancer Panel circulating tumor DNA (ctDNA) test launched at the American Association of Cancer Research 2019 annual meeting, Sysmex Inostics has updated the test to provide additional key information for investigation of the validity ...
mehrNew in-vivo study confirms that ciliate vaccine protects against flu
mehrBrenntag and KRONOS enter into an exclusive Sales & Marketing partnership on Titanium Dioxide for Life Science segment in Asia Pacific
Dear all, Please find attached Brenntag's press release regarding the exclusive distribution agreement for KRONOS specialty Titanium Dioxide grades marketed into the Pharma, Personal Care, and Food and Nutrition industries in ...
mehrBrenntag and INABATA FRANCE SAS announce exclusive distribution partnership in the DACH region
Dear all, Please find attached Brenntag's press release regarding the exclusive sales and marketing distribution partnership of Brenntag GmbH and INABATA France SAS for INABATA's cosmetic actives ingredients in Germany, Austria and Switzerland (DACH). For further information ...
mehrEuropean Association of E-Pharmacies (EAEP)
EAMSP kicks off information campaign about digitization in German healthcare sector / Fighting the allergic reaction to anything new with #neuschnupfen
mehrWorldwide first and only shotgun lipidomics service provider with official GMP certificate
Dresden / Germany (ots) - Good Manufacturing Practices (GMP) ensure safety and quality of pharmaceutical products. Lipotype is the worldwide first and only officially GMP certified shotgun lipidomics service provider for pharmaceutical applications. Quality variations can pose direct threats to patient health - especially in the pharma industry. This is why quality ...
mehrBrenntag to distribute innovative ESTERLAC emulsifier and surfactant range for cosmetic industry in Europe
Dear all, Please find attached a press release of Brenntag regarding the distribution of Corbion´s newly launched range of ESTERLAC (Trademark) emulsifiers and surfactants to cosmetics customers in key European markets. For ...
mehrMundipharma EDO GmbH: US FDA Grants Orphan Drug Designation for Tinostamustine in Very Rare Blood Cancer
Basel, Switzerland (ots/PRNewswire) - FOR EX-US MEDICAL AND TRADE MEDIA ONLY - T-cell prolymphocytic leukaemia is an extremely rare and aggressive T-cell leukaemia, with very limited effective treatment options1,2 - Tinostamustine is in very early phase clinical trials to investigate it as a potential future ...
mehrLEUKOCARE Announces Appointment of Dr Andreas Seidl as new Chief Operating Officer and member of the Executive Board
Munich, Germany (ots) - Dr Andreas Seidl, hired as new Chief Operating Officer and member of the Executive Board, will be responsible for managing R&D operations as well as quality and regulatory, logistics and intellectual property of LEUKOCARE AG. He will assume his new role on April 1, 2019. Munich-based ...
mehrA new force in the European chemical and pharmaceutical engineering sector: TTP AG is now also acquiring the French subsidiary of NNE A/S
Frankfurt am Main/Copenhagen (ots) - TTP AG, Frankfurt/Main and its subsidiary TTP France S.A.S. are now also acquiring NNE S.A.S., the French engineering arm of the Danish company NNE A/S with 87 employees at the pharmaceutical industry sites in Paris, Lyon and Chartres. Three weeks ago, TTP AG and NNE A/S ...
mehrSysmex Inostics' OncoBEAM(TM) demonstrates clinical validity and superior performance versus pan-cancer NGS for blood-based mutation detection for hepatocellular carcinoma
Hamburg, Germany (ots) - Data recently published in Clinical Cancer Research (http://ots.de/0ZGZkf) the advantages of using an ultra-high sensitivity test for detection of mutations which may predict therapeutic efficacy for hepatocellular carcinoma (HCC). Sysmex Inostics' OncoBEAM technology, a highly clinically ...
mehrPHARMAPLAN returns: TTP AG buys European engineering companies from NNE A/S
Frankfurt am Main / Copenhagen (ots) - TTP AG, Frankfurt/Main and it's subsidiary TTP GmbH, has signed an agreement with the Danish NNE A/S in Copenhagen for the purchase of three NNE subsidiaries based in Switzerland, Germany and Belgium. TTP AG is an operational holding company specialising in production-related engineering services for the process industry. It is ...
mehrDr. Klemens Schulz appointed CPO of the L&R Corporate Group
mehrSysmex Inostics' OncoBEAM(TM) liquid biopsy technology demonstrates utility for clinical management of melanoma patients undergoing treatment with targeted therapy and immune checkpoint inhibitors
Hamburg, Germany (ots) - Sysmex Inostics, a pioneer in blood-based circulating tumor DNA (ctDNA) analysis and molecular diagnostics for oncology, is pleased to announce publication of a study in the Journal of Molecular Oncology highlighting the important clinical value of blood-based ctDNA mutation testing to ...
mehrB. Braun Medical acquires Dismed's hand sanitizer and intravenous fluid businesses in South Africa / Commitment to growth and local manufacturing for the African healthcare sector
Melsungen/Johannesburg (ots) - On 30 June 2016, B. Braun Medical, the South African subsidiary of the German B. Braun Group, completed its acquisition of Dismed Pharmaceutical (Pty) Ltd and Dismed Criticare (Pty) Ltd, both out of business rescue. With over 600 employees in South Africa, B. Braun specialises in the ...
mehrEuropean Society for Medical Oncology (ESMO)
ESMO announces annual medical oncology congress platform in Europe from 2016
Lugano, Switzerland (ots) - The European Society for Medical Oncology, the pan-European association representing medical oncologists in Europe and beyond, has announced that it will be organising an annual Congress in Europe from 2016. A record 19,809 participants from 134 countries gathered at ESMO 2014 in Madrid to hear the results of trials which included ...
mehrEckert & Ziegler Strahlen und Medizintechnik AG
Eckert & Ziegler awarded contract to produce new type of medicine to fight pancreatic cancer
Berlin (ots) - Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700) is engaging with a USA based biotech company to become a contract manufacturer for a new type of cancer treatment and is creating a new production plant for this purpose at its Braunschweig location with financial support provided by the customer. The cooperation enfolds a brand-new ...
mehrBoehringer Ingelheim's afatinib Achieves Primary Endpoint in Global Phase III Study in Recurrent/Metastatic Head and Neck Squamous Cell Cancer
Ingelheim, Germany (ots/PRNewswire) - - Results from the LUX-Head & Neck 1 study show afatinib* significantly delayed tumour growth versus chemotherapy in patients following failure of their previous treatment, reducing the risk for disease progression by 20% - Head and neck cancer has a very poor prognosis with no ...
mehrNew UK sales subsidiary for Dr. Hauschka: WALA UK Ltd.
Bad Boll/Eckwälden (ots) - Dr. Hauschka, a brand marketed by the traditional German company WALA Heilmittel GmbH, is now able to boost its presence on the UK market. A newly established subsidiary, WALA UK Ltd., which is based in Oxfordshire near London, will be marketing and distributing the premium natural and organic cosmetics products as of 1 January. Dr. Hauschka enthusiasts will be able to find a wide range of ...
mehrFresenius achieves record Q3 earnings - improves 2011 earnings outlook
Bad Homburg (ots) - Q1-3 2011: - Sales EUR 12.1 billion, +2% at actual rates, +5% in constant currency - EBIT EUR 1,862 million, +5% at actual rates, +9% in constant currency - Net income EUR 565 million, +14% at actual rates, +17% in constant currency - Fresenius improves 2011 earnings1 outlook of 15% ...
Ein DokumentmehrPrehospital Thrombolysis for AMI to be Studied in New Clinical Trial / Study will investigate concept that prehospital lysis can be at least as good as primary PCI
Ingelheim, Germany (ots) - For scientific media outside the USA, Canada and Japan Boehringer Ingelheim announced today that it is undertaking a new initiative in the treatment of heart attack (ST-segment elevation myocardial infarction or STEMI). The company will sponsor a new clinical trial known as ...
mehrGirindus AG - Oligonucleotide Production Expansion Accelerated
Bensberg (ots) - Girindus, with core competencies in process development, scale up and manufacture of innovative drug and cosmetic actives, sees a significant increase in demand for its commercial oligonucleotide production capabilities in the USA and Europe. "Our know-how and our technical expertise in the area of oligonucleotide research, development and manufacturing has been validated by an increased market ...
mehrFresenius Medical Care AG & Co. KGaA
Fresenius Medical Care AG reports Fourth Quarter and Full Year Results 2003
Bad Homburg, Germany (ots) - Summary Full Year 2003: Company met or exceeded financial targets for 2003 and will propose 7th consecutive dividend increase Net Revenues $ 5,528 million + 9% Operating income (EBIT) $ 757 million + 9% Net income $ 331 million + 14% Operating Cash Flow $ ...
mehrFresenius announces results of Financial Year 2002
Bad Homburg (ots) - - Sales: + 3 % to Euro 7.5 billion currency-adjusted: + 9 % - EBIT: + 10 %* to Euro 837 million - Net income: + 44 %* to Euro 134 million - Dividend: + 10 % to Euro 1.14 per ordinary share and Euro 1.17 per preference share The Fresenius health care group increased sales in the 2002 financial year by a plus ...
mehr